Combined aerobic and resistance training

Studies of combined aerobic and resistance training in people

172 studies gave combined aerobic and resistance training to people and measured what changed

What changedDesignPeopleSource

no change: Has no effect on functional capacity6-minute walking distance between-group p=0.55

Randomized trial12 weeks13 peopleParticipants with severe obesity after bariatric surgeryResearch Square, Nov 20, 2026

up: Increases placental KlothoAdjusted mean difference approximately 101 pg/mL versus usual care

Trialearly-mid pregnancy until birth76 peopleWomenPregnancymedRxiv, Nov 2, 2026

up: Increases peak oxygen uptake+4.0±3.1 mL/min/kg

no change: Has no effect on supine heart rate76±9 versus 74±9 beats/min; p=0.218

down: Decreases heart rate increase upon standing33±12 versus 25±10 beats/min; p=0.002

Trial3 months31 peopleBoth28±7 years at enrollmentPostural orthostatic tachycardia syndromeAHA Scientific Sessions 2026 abstract, Nov 2, 2026

down: Decreases fasting glucose

up: Increases progressive sperm motilityBetween-group difference in change: 4.55 percentage points, 95% CI 3.66 to 5.44

up: Increases total testosterone

Trial12 weeks34 peopleMen18–24 yearsHealthy menJournal of clinical medicine, Oct 29, 2026

up: Improves muscle strength

down: Decreases blood pressure

down: Decreases redox-related DNA methylation

Trial14 weeks45 peopleWomenmiddle-aged and olderMidlife adults; Older adults; physically inactive women; single-arm studyAntioxidants (Basel, Switzerland), Oct 27, 2026

down: Decreases body fat percentageAdjusted difference −2.15 percentage points; 95% CI −2.75 to −1.56

up: Increases VO2MAX

down: Decreases insulin resistance

Randomized trial8 weeks30 peopleWomen20–39 yearsNormal-weight obesityMetabolites, Oct 26, 2026

down: Decreases syncope events0–3 events in the interval group vs 0–4 in the continuous group

Randomized trial6-week training; 6-month follow-up48 peopleBothVasovagal syncope type 1 without cardioinhibition and confirmed autoimmune diseaseESC Congress 2026 abstract, Oct 26, 2026

up: Improves lower limb muscle strength

up: Improves quality of life

Randomized trial8 weeks68 peopleBreast cancer patients with chemotherapy-induced peripheral neuropathyPain management nursing : official journal of the American Society of Pain Management Nurses, Oct 22, 2026

up: Improves physical function

up: Improves body composition

Trial12 weeks84 peoplemean age 83.13 ± 7.63 yearsOlder adults; institutionalized older adultsHealthcare (Basel, Switzerland), Oct 21, 2026

up: Improves cognitive function

Randomized trial12 weeks54 peopleWomen≥65 yearsOlder adults; obesityJournal of obesity & metabolic syndrome, Oct 20, 2026

down: Decreases 24-hour systolic average real variability−2 ± 1 mmHg

Randomized trial12 weeks20 peopleBoth50–80 yearsMidlife adults; Older adults; hypertension; within-group change over timeFrontiers in rehabilitation sciences, Oct 19, 2026

up: Increases flow-mediated vasodilation

up: Increases nitric oxide

no change: Has no effect on nitric oxide

Randomized trial12 weeks20 peopleolder adultsOlder adults; type 2 diabetes; comparison with baselineFrontiers in endocrinology, Oct 16, 2026

down: Decreases 24-hour mean glucoseβ = -0.513; Bonferroni-corrected p = 0.017

up: Increases time in range

Randomized trial24 hours23 peopleolder adultsOlder adults; type 2 diabetes mellitus; exploratory analysisJournal of science and medicine in sport, Oct 15, 2026

down: Decreases fat mass

up: Increases muscle mass

Randomized trial12 weeks13 peopleWomenPostmenopausal womenExperimental gerontology, Oct 10, 2026

down: Decreases frailty

up: Improves quality of life

Randomized trial12 weeks120 peopleolder adultsOlder adults; frailty syndromeChinese Journal of Gerontology, Oct 8, 2026

up: Improves handgrip strength+3.78 kg

up: Increases rectus femoris cross-sectional area

down: Decreases fat tissue mass40.3 to 36.7 kg

Treated cohortsix-month17 peopleClinically stable adults with end-stage kidney disease (ESKD) on maintenance hemodialysisResearch Square, Sep 30, 2026

down: Decreases triglycerideMD -0.255, 95% CI -0.355 to -0.156

Review of trials4,483 people pooledGeneral populationMetabolites, Sep 17, 2026

down: Decreases body fat percentage-2.04 percentage points, 95% CI -2.94 to -1.14

up: Improves estimated VO2max

Randomized trial12 weeks108 peoplewomen40–77 yearsWomen aged 40–77 yearsJournal of the International Society of Sports Nutrition, Sep 14, 2026

up: Improves upper- and lower-limb strength

Randomized trial16 weeks42 peopleWomenBreast cancer survivorsCancer treatment and research communications, Sep 7, 2026

up: Improves health-related quality of lifeMD 7.96, 95% CI 2.95–12.96

up: Improves exercise capacityMD 51.10, 95% CI 16.04–86.16

Review of trials8 to 96 weeks806 people pooledAdult male patientsProstate cancer patients receiving androgen deprivation therapy (ADT)Frontiers in oncology, Aug 17, 2026

up: Increases lean body mass

Randomized trial8 weeks16 peopleWomenResearch Square, Aug 12, 2026

up: Increases Isthmin 1

Randomized trial12 weeks11 peopleMen23-32 yearsObesityBMC sports science, medicine & rehabilitation, Aug 12, 2026

up: Improves postural stability+6.5 vs +2.7 points, partial eta-squared=0.58

up: Improves dual-task Timed Up and Go performance-5.2 vs -1.5 s, partial eta-squared=0.55

Randomized trialeight weeks15 people55-75 yearsOlder adults; in older adults with cognitive impairmentInternational Journal of Advanced Research and Multidisciplinary Trends (IJARMT), Aug 11, 2026

no change: Has no effect on C-reactive proteinSMD = −0.42, 95% CrI: −1.26 to 0.42

Review of trials6 weeks to 12 months2,836 people pooledmean age of 76.98 yearsPredominantly older adults with chronic disease, with the remainder comprising healthy older adults and populations with mixed or unspecified health statusFrontiers in medicine, Aug 6, 2026

up: Improves cardiometabolic fitness

down: Decreases very-long-chain ceramides

down: Decreases ceramide

Randomized trial12 weeks29 peopleMen and postmenopausal women with overweight or obesity and type 2 diabetesDiabetologia, Aug 5, 2026

down: Decreases HbA1cMD = -1.05%

down: Decreases fasting blood glucoseMD = -1.44 mmol/L

down: Decreases 2-hour postprandial glucoseMD = -3.15 mmol/L

Review of trials2,461 people pooledBothat least 60 yearsOlder adults; older adults with type 2 diabetes mellitusFrontiers in endocrinology, Jul 15, 2026

up: Increases adiponectinmean change 1.23 (95% CI 0.98-1.49) NMSE; 0.86 (95% CI 0.31-1.40) MSE; d = 1.04 and 0.71

up: Increases FGF21mean change 16.75 (95% CI 5.46-28.05); d = 0.40

down: Decreases FGF21mean change -15.91 (95% CI -28.35 to -3.48); d = -0.33

Randomized trial10 weeks60 peopleWomen75.2 ± 4.3 yearsOlder adults; in both exercise groups (NMSE and MSE)The journal of nutrition, health & aging, Jul 4, 2026

no change: Has no effect on PAI-124.69±16.77 to 29.81±8.83; p=.1667

no change: Has no effect on C-reactive protein0.91±1.64 to 0.41±0.16; p=.2198

no change: Has no effect on fasting blood glucose

Trial24 weeks15 peopleWomenmean 56.27 yearsMidlife adults; Postmenopausal women; Postmenopausal women with regular physical activity experience; single-group before-and-after comparisonJournal of Coaching Development, Jun 30, 2026

no change: Has no effect on arterial stiffness

no change: Has no effect on hemodynamic parameters

Randomized trial16 weeksOlder adults; previously trained grade 1 hypertensionCanadian geriatrics journal : CGJ, May 29, 2026

up: Increases adropinp = 0.03

down: Decreases cardio-ankle vascular indexp = 0.01

Randomized trial12 weeks30 peopleWomen50-65 yearsOlder adults; Postmenopausal women; type 2 diabetesBMC sports science, medicine & rehabilitation, May 14, 2026

down: Decreases serum cadmium-0.056 μg/L (-63%)

Trial14 weeks32 peopleWomen50-70 yearsOlder adults; lower aerobic fitnessEpigenomics, May 14, 2026

no change: Has no effect on chemotherapy induced peripheral neuropathy

no change: Has no effect on cancer-related fatigue

no change: Has no effect on handgrip strength

Randomized trial8 weeks27 peopleColorectal cancer patients receiving chemotherapyClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, Apr 30, 2026

down: Decreases fat mass-11.9% ± 5.7% vs. -10.1% ± 4.9%; ES -0.64 [-0.85, -0.40]

Randomized trial26 weeks58 peopleBoth18-65 yearsFollowing metabolic bariatric surgeryJournal of cachexia, sarcopenia and muscle, Apr 30, 2026

down: Decreases body weight

Randomized trial12 weeks45 peopleWomen50–65 yearsPostmenopausal women; Midlife adults; Older adults; overweight or obesityExploration of Endocrine and Metabolic Diseases, Apr 30, 2026

down: Decreases tremor

up: Improves six-minute walk test

down: Decreases vitamin D3

Trial8 weeks28 peopleParkinson's diseaseNeuroRehabilitation, Apr 10, 2026

down: Decreases triglyceride

Randomized trial12 weeks83 peopleWomen40–77 yearsMidlife adults; Older adults; larger TG decrease than with resistance trainingResearch Square, Mar 25, 2026

up: Increases estimated glomerular filtration rate5.2 mL/min/1.73 m2 (95%CI: 0.9-9.5, p = 0.019)

no change: Has no effect on albumin

Randomized trial9 months136 peopleBothaged 41-87 yearsMidlife adults; Older adults; The oldest old; type 2 diabetes without kidney diseaseDiabetes & metabolic syndrome, Mar 24, 2026

down: Decreases body weight

up: Improves muscle strength

up: Increases non-exercise activity thermogenesis

Randomized trialthrough week 3257 peopleFifty-seven womenaverage age of 65.3 ± 3.4 yearsHealthy, nonsmoking, sedentary older women free of metabolic diseasesEuropean journal of applied physiology, Mar 24, 2026

up: Increases CD8+ EMRA cells

down: Decreases CD8+ naive T cells

down: Prevents insulin

Trial12 weeks11 peoplewomen49.1 ± 14.4 yearsWomen with early-stage breast cancer undergoing (neo)adjuvant treatmentResearch Square, Mar 20, 2026

up: Increases maximal oxygen uptakeP < .01

Trialfour years25 peopleMen66 ± 7 yearsOlder adultsThe American journal of medicine, Mar 9, 2026